You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Niacin: The Evidence, Clinical Use, and Future Directions
|
|---|---|
| Published in |
Current Atherosclerosis Reports, October 2011
|
| DOI | 10.1007/s11883-011-0212-1 |
| Pubmed ID | |
| Authors |
Todd C. Villines, Andrew S. Kim, Rosco S. Gore, Allen J. Taylor |
| Abstract |
The use of FDA-approved niacin (nicotinic acid or vitamin B3) formulations at therapeutic doses, alone or in combination with statins or other lipid therapies, is safe, improves multiple lipid parameters, and reduces atherosclerosis progression. Niacin is unique as the most potent available lipid therapy to increase high-density lipoprotein (HDL) cholesterol and it significantly reduces lipoprotein(a). Through its action on the GPR109A receptor, niacin may also exert beneficial pleiotropic effects independent of changes in lipid levels, such as improving endothelial function and attenuating vascular inflammation. Studies evaluating the impact of niacin in statin-naïve patients on cardiovascular outcomes, or alone and in combination with statins or other lipid therapies on atherosclerosis progression, have been universally favorable. However, the widespread use of niacin to treat residual lipid abnormalities such as low HDL cholesterol, when used in combination with statins among patients achieving very low (<75 mg/dL) low-density lipoprotein cholesterol levels, is currently not supported by clinical outcome trials. |
Mendeley readers
The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 1 | 2% |
| Unknown | 61 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 13 | 21% |
| Student > Bachelor | 12 | 19% |
| Student > Master | 8 | 13% |
| Researcher | 7 | 11% |
| Student > Doctoral Student | 3 | 5% |
| Other | 8 | 13% |
| Unknown | 11 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 42% |
| Agricultural and Biological Sciences | 10 | 16% |
| Biochemistry, Genetics and Molecular Biology | 4 | 6% |
| Nursing and Health Professions | 2 | 3% |
| Chemistry | 2 | 3% |
| Other | 7 | 11% |
| Unknown | 11 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 January 2024.
All research outputs
#5,298,603
of 25,168,110 outputs
Outputs from Current Atherosclerosis Reports
#271
of 854 outputs
Outputs of similar age
#28,891
of 145,770 outputs
Outputs of similar age from Current Atherosclerosis Reports
#5
of 9 outputs
Altmetric has tracked 25,168,110 research outputs across all sources so far. Compared to these this one has done well and is in the 78th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 854 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.3. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 145,770 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.